Worthing-based Allergy Therapeutics has struck a multi-drug co-development partnership with pharmaceutical services and drug development company Ergomed.
The multi-product, multi-study partnership will support the commercialisation of Allergy Therapeutics’ OralVac platform.
The co-development collaboration will include clinical studies, from phase I to phase III, of three OralVac products: house dust mite; tree pollen; and grass pollen. It is scheduled to run for seven years and start in 2018.
Under the terms of the agreement, Allergy Therapeutics will pay Ergomed a fee for conducting clinical development activities and Ergomed will contribute in-kind to the development cost. In return, Ergomed will receive future tiered royalties for each product.
Dr Miroslav Reljanovic, executive vice-chairman of Ergomed, said: “We are excited to join in the further development of these products which have established an important presence in the market.
“Ergomed has extensive experience in conducting clinical research in the field of allergy therapies, and so this is a natural therapy area for our next co-development project.”
Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, added: “Ergomed has an excellent track record in successfully completing specialist studies and particular experience with allergy products. We’re pleased to be working with the team and look forward to jointly accelerating the licencing of OralVac products in Europe.”